Restricted accessResearch articleFirst published online 2016-5
A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients
The lack of head-to-head clinical studies powered to compare atomoxetine and osmotic release oral system (OROS) methylphenidate necessitates treatment comparison by methods that include indirect evidence such as network meta-analysis (NMA). A NMA assessing the relative treatment effects of atomoxetine and OROS methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD) was conducted. Studies were identified by systematic literature review. Analyses summarised improvements in efficacy, measured by ADHD-specific scales, using Cohen’s d to calculate the standardised mean difference (SMD), and all cause discontinuations. Results showed effect sizes (SMD, 95% credible interval (CrI)) relative to placebo that did not differ significantly between atomoxetine (0.46, 0.36–0.56) and OROS methylphenidate (0.51, 0.40–0.63) in clinical studies of up to 12 weeks’ duration (SMD, 95% CrI for atomoxetine versus OROS methylphenidate: –0.05, –0.18–0.08). Patients treated with these medications responded better than those given placebo across all analyses. There was also no significant difference in discontinuation rates between atomoxetine and OROS methylphenidate (odds ratio, 95% CrI: 0.85, 0.53–1.35). Between-study heterogeneity was low overall. Results of this NMA suggest that the efficacy of atomoxetine and OROS methylphenidate in adults does not differ significantly. Clinical guidelines may require amendment to reflect these recent data.
AdlerLTanakaYWilliamsD. (2014) Executive function in adults with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled, withdrawal study. J Clin Psychopharmacol34: 461–466.
2.
AdlerLALiebowitzMKronenbergerW (2009a) Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety26: 212–221.
3.
AdlerLASpencerTBrownTE (2009b) Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: A 6-month, double-blind trial. J Clin Psychopharmacol29: 44–50.
4.
AdlerLASpencerTJWilliamsDW (2008) Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: Final report of a 4-year study. J Atten Disord12: 248–253.
5.
AdlerLAZimmermanBStarrHL. (2009c) Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol29: 239–247.
6.
BiedermanJMickESurmanC. (2006) A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry59: 829–835.
7.
BiedermanJMickESurmanC. (2010) A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol30: 549–553.
8.
BitterISimonVBálintS (2010) How do different diagnostic criteria, age and gender affect the prevalence of attention deficit hyperactivity disorder in adults? An epidemiological study in a Hungarian community sample. Eur Arch Psychiatry Clin Neurosci260: 287–296.
9.
Bolea-AlamanacBNuttDJAdamouM. (2014) Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol28: 179–203.
10.
CastellsXCunillRCapellaD (2013) Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: A meta-analysis of randomized clinical trials. Eur J Clin Pharmacol69: 347–356.
11.
CastellsXRamos-QuirogaJARigauD. (2011) Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: A meta-regression analysis. CNS Drugs25: 157–169.
12.
ChangZLichtensteinPD’OnofrioBM. (2014) Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: A population-based study. JAMA Psychiatry71: 319–325.
13.
CoghillDSethS (2006) Osmotic, controlled-release methylphenidate for the treatment of ADHD. Expert Opin Pharmacother7: 2119–2138.
14.
CohenJ (1988) Statistical Power Analysis for the Behavioral Sciences. 2. Hillsdale, NJ: Eribaum.
CunillRCastellsXTobiasA. (2013) Atomoxetine for attention deficit hyperactivity disorder in the adulthood: A meta-analysis and meta-regression. Pharmacoepidemiol Drug Saf22: 961–969.
17.
DeberdtWThomeJLebrecJ. (2015) Prevalence of ADHD in non-psychotic adult psychiatric care (ADPSYC): A multinational cross-sectional study in Europe. BMC Psychiatry15: 242.
18.
DerSimonianRLairdN (1986) Meta-analysis in clinical trials. Control Clin Trials7: 177–187.
19.
DuPaulGJPowerTJAnastopoulosAD. (1998) ADHD Rating Scale-IV. Checklist, Norms, and Clinical Interpretations. New York, NY: Guilford.
20.
DurellTMAdlerLAWilliamsDW (2013) Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: A randomized, double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol33: 45–54.
FaraoneSVGlattSJ (2010) A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry71: 754–763.
23.
FaraoneSVPerlisRHDoyleAE. (2005) Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry57: 1313–1323.
24.
FayyadJDe GraafRKesslerR (2007) Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry190: 402–409.
25.
GajriaKLuMSikiricaV. (2014) Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder – a systematic literature review. Neuropsychiatr Dis Treat10: 1543–1569.
26.
GotoTHirataYTakitaY. (2013) Efficacy and safety of atomoxetine hydrochloride in Asian adults with ADHD: A multinational 10-week randomized double-blind placebo-controlled Asian study. J Atten Disord Epub ahead of print 7November2013. DOI: 10.1177/1087054713510352.
27.
HarrisJBradburnMDeeksJ. (2008) Metan: Fixed- and random-effects meta-analysis. Stata J8: 3–28
28.
HigginsJPTThompsonSGDeeksJJ. (2003) Measuring inconsistency in meta-analyses. Br Med J327: 557–560.
29.
JansenJTrikalinosTCappelleriJ. (2014) Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: An ISPOR-AMCP-NPC good practice task force report. Value Health17: 157–173.
30.
JensenPSArnoldLESwansonJM. (2007) 3-Year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry46: 989–1002.
31.
KesslerRCAdlerLAmesM (2005a) The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ Med47: 565–572.
32.
KesslerRCAdlerLAmesM. (2005b) The World Health Organization Adult ADHD Self-Report Scale (ASRS): A short screening scale for use in the general population. Psychol Med35: 245–256.
33.
KesslerRCAdlerLBarkleyR (2006) The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication. Am J Psychiatry163: 716–723.
34.
KoestersMBeckerTKilianR. (2009) Limits of meta-analysis: Methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol23: 733–744.
35.
KonsteniusMJayaram-LindstromNBeckO. (2010) Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: A pilot study. Drug Alcohol Depend108: 130–133.
36.
KooijSJBejerotSBlackwellA (2010) European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry10: 67.
37.
LeuchtSCiprianiASpineliL. (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet382: 951–962.
38.
LichtensteinPHalldnerLZettergvistJ. (2012) Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med367: 2006–2014.
39.
LunnDJThomasABestN. (2000) Winbugs: A Bayesian modelling framework: Concepts, structure, and extensibility. Stat Comput10: 325–337.
40.
McRae-ClarkALCarterREKilleenTK. (2010) A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder. Am J Addict19: 481–489.
MedoriRRamos-QuirogaJACasasM. (2008) A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry63: 981–989.
43.
MichelsonDAdlerLSpencerT. (2003) Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. Biol Psychiatry53: 112–120.
44.
MillsEThorlundKIoannidisJ (2013) Demystifying trial networks and network meta-analysis. Br Med J346: f2914.
45.
MoherDLiberatiATetzlaffJ., PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med6: e1000097.
46.
National Institute for Health and Care Excellence (NICE) (2008) Attention Deficit Hyperactivity Disorder: The NICE Guideline on Diagnosis and Management of ADHD in Children, Young People and Adults 2008. London: National Institute for Health and Care Excellence Available at: http://www.nice.org.uk/guidance/cg72 (accessed 1 August 2013).
Ng-MakDRajagopalanMcLeodE. (2014) Comparative efficacy and cardiometabolic profile of antipsychotic monotherapy for the treatment of bipolar depression: A network meta-analysis. Poster 219. 27th Annual US Psychiatric and Mental Health Congress, Orlando, FL, 20–23 September 2014.
49.
Ramos-QuirogaJALopez-RameroPBusheC (2014) Response to Cunill et al. Pharmacoepidemiol Drug Saf23: 435–436.
50.
RaoPPlaceM (2011) Prevalence of ADHD in four general adult outpatient clinics in North East England. Prog Neurol Psychiatry15: 7–10.
51.
RoskellNSSetyawanJZimovetzEA. (2014) Systematic evidence synthesis of treatments for ADHD in children and adolescents: Indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine. Curr Med Res Opin30: 1673–1685.
52.
RöslerMFischerRAmmerR. (2009) A randomised, placebo-controlled, 24-week study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci259: 120–129.
53.
RöslerMRetzWRetz-JungingerP. (2008) Attention deficit hyperactivity disorder in adults. Benchmarking diagnosis using the Wender-Reimherr adult rating scale. Nervenarzt79: 320–327.
54.
Scottish Intercollegiate Guidelines Network (SIGN) (2009) National Clinical Guideline 112: Management of Attention Deficit and Hyperkinetic Disorders in Children and Young People: A National Clinical Guideline. Available at: www.sign.ac.uk/pdf/sign112.pdf (accessed 25 November 2014).
55.
SobanskiELeppämäkiSBusheC. (2014) Patterns of response to atomoxetine for the treatment of adult patients with attention deficit hyperactivity disorder (abstract REPA-0455). Eur Psychiatry29: EPA–0455.
56.
SpencerTJAdlerLAMeihua Qiao. (2010) Validation of the adult ADHD investigator symptom rating scale (AISRS). J Atten Disord14: 57–68.
57.
SutherlandSMAdlerLAChenC. (2012) An 8-week, randomized controlled trial of atomoxetine, atomoxetine plus buspirone, or placebo in adults with ADHD. J Clin Psychiatry73: 445–450.
58.
SuttonAAdesAECooperN. (2008) Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics26: 753–767.
UpadhyayaHRamos-QuirogaAAdlerLA (2013) Maintenance of response after open-label treatment with atomoxetine hydrochloride in international European and non-European adult outpatients with attention deficit/hyperactivity disorder: A placebo-controlled, randomized withdrawal study. Eur J Psychiatry27: 185–205.
61.
WeislerRHPandinaGJDalyEJ. (2012) Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs26: 421–434.
62.
WilensTAdlerLTanakaY. (2011) Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: Exploratory analysis of a placebo-controlled trial of atomoxetine. Curr Med Res Opin27: 2309–2320.
63.
WilensTEAdlerLAWeissMD (2008) Atomoxetine ADHD/SUD Study Group. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend96: 145–154.
64.
WinhusenTMSomozaECBrighamGS. (2010) Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry71: 1680–1688.
65.
YoungJLSarkisEQiaoM. (2011) Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: A 24-week, randomized, double-blind, placebo controlled trial. Clin Neuropharmacol34: 51–60.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
